_1777294237270_124456903.png&w=48&q=75){kind=small}
Al Watan approves Fundayo for obesity treatment
The General Authority for Food and Drugs announced the approval of the registration of the medication "Fondayo" for the treatment of obesity and weight gain associated with health risk factors. The medication, which contains the active ingredient Orforglieberon, is intended to reduce appetite and achieve sustained weight loss when used alongside a healthy diet and regular physical activity. Clinical studies have shown that the highest dose of "Fondayo" at 36 mg resulted in weight loss of up to 11.2% over 72 weeks in patients without diabetes, and 9.6% in those with type 2 diabetes. The most common side effects include gastrointestinal disturbances, which are generally mild to moderate. Use should be under medical supervision, and individuals with a family or personal history of thyroid tumors should avoid it. The approval aims to provide modern treatment options to support healthcare improvement efforts and help achieve the goals of Saudi Vision 2030.
Notice: This Is an AI-Generated Summary
Comments (0)